Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Cash & Equivalents: 2020-2024

Historic Cash & Equivalents for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $8.9 million.

  • SAB Biotherapeutics' Cash & Equivalents rose 219.83% to $29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.4 million, marking a year-over-year increase of 219.83%. This contributed to the annual value of $8.9 million for FY2024, which is 84.27% down from last year.
  • SAB Biotherapeutics' Cash & Equivalents amounted to $8.9 million in FY2024, which was down 84.27% from $56.6 million recorded in FY2023.
  • SAB Biotherapeutics' 5-year Cash & Equivalents high stood at $56.6 million for FY2023, and its period low was $8.9 million during FY2024.
  • For the 3-year period, SAB Biotherapeutics' Cash & Equivalents averaged around $26.8 million, with its median value being $15.0 million (2022).
  • In the last 5 years, SAB Biotherapeutics' Cash & Equivalents soared by 275.93% in 2023 and then plummeted by 84.27% in 2024.
  • SAB Biotherapeutics' Cash & Equivalents (Yearly) stood at $12.6 million in 2020, then skyrocketed by 163.33% to $33.2 million in 2021, then crashed by 54.69% to $15.0 million in 2022, then surged by 275.93% to $56.6 million in 2023, then crashed by 84.27% to $8.9 million in 2024.